» Articles » PMID: 36759822

"Two Birds with One Stone" Strategy for the Lung Cancer Therapy with Bioinspired AIE Aggregates

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2023 Feb 10
PMID 36759822
Authors
Affiliations
Soon will be listed here.
Abstract

Aggregation-induced emission luminogens (AIEgens) have emerged as novel phototherapeutic agents with high photostability and excellent performance to induce photodynamic and/or photothermal effects. In this study, a zwitterion-type NIR AIEgens CHNOS (named BITT) with biomimetic modification was utilized for lung cancer therapy. The tumor-associated macrophage (TAM)-specific peptide (CRV) was engineered into the lung cancer cell-derived exosomes. The CRV-engineered exosome membranes (CRV-EM) were obtained to camouflage the BITT nanoparticles (CEB), which targeted both lung cancer cells and TAMs through homotypic targeting and TAM-specific peptide, respectively. The camouflage with CRV-EM ameliorated the surface function of BITT nanoparticles, which facilitated the cellular uptake in both cell lines and induced significant cell death in the presence of laser irradiations in vitro and in vivo. CEB showed improved circulation lifetime and accumulations in the tumor tissues in vivo, which induced efficient photodynamic and photothermal therapy. In addition, CEB induced the tumor microenvironment remodeling as indicated by the increase of CD8 + and CD4 + T cells, as well as a decrease of M2 TAM and Myeloid-derived suppressor cells (MDSCs). Our work developed a novel style of bioinspired AIE aggregates, which could eliminate both lung cancer cells and TAMs, and remodel the tumor environments to achieve an efficient lung cancer therapy. To the best of our knowledge, we are the first to use this style of bioinspired AIE aggregates for photo-mediated immunotherapy in lung cancer therapy.

Citing Articles

Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy.

Guan X, Xu X, Tao Y, Deng X, He L, Lin Z J Nanobiotechnology. 2024; 22(1):692.

PMID: 39523308 PMC: 11552110. DOI: 10.1186/s12951-024-02967-7.


Nanomedicines Targeting Tumor Cells or Tumor-Associated Macrophages for Combinatorial Cancer Photodynamic Therapy and Immunotherapy: Strategies and Influencing Factors.

Wei Y, Li R, Wang Y, Fu J, Liu J, Ma X Int J Nanomedicine. 2024; 19:10129-10144.

PMID: 39381025 PMC: 11460276. DOI: 10.2147/IJN.S466315.


Recent advances to address challenges in extracellular vesicle-based applications for lung cancer.

Huang G, Zheng W, Zhou Y, Wan M, Hu T Acta Pharm Sin B. 2024; 14(9):3855-3875.

PMID: 39309489 PMC: 11413688. DOI: 10.1016/j.apsb.2024.06.010.


Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects.

Zhang J, Sun Y, Li Y, Han J Heliyon. 2024; 10(16):e36388.

PMID: 39253229 PMC: 11382172. DOI: 10.1016/j.heliyon.2024.e36388.


Exosomes: efficient macrophage-related immunomodulators in chronic lung diseases.

Kang J, Hua P, Wu X, Wang B Front Cell Dev Biol. 2024; 12:1271684.

PMID: 38655063 PMC: 11035777. DOI: 10.3389/fcell.2024.1271684.


References
1.
Li H, Li S, Lin Y, Chen S, Yang L, Huang X . Artificial exosomes mediated spatiotemporal-resolved and targeted delivery of epigenetic inhibitors. J Nanobiotechnology. 2021; 19(1):364. PMC: 8597284. DOI: 10.1186/s12951-021-01107-9. View

2.
Chen X, Gao H, Deng Y, Jin Q, Ji J, Ding D . Supramolecular Aggregation-Induced Emission Nanodots with Programmed Tumor Microenvironment Responsiveness for Image-Guided Orthotopic Pancreatic Cancer Therapy. ACS Nano. 2020; 14(4):5121-5134. DOI: 10.1021/acsnano.0c02197. View

3.
Bart V, Pickering R, Taylor P, Ipseiz N . Macrophage reprogramming for therapy. Immunology. 2020; 163(2):128-144. PMC: 8114216. DOI: 10.1111/imm.13300. View

4.
Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

5.
Li H, Peng Q, Yang L, Lin Y, Chen S, Qin Y . High-Performance Dual Combination Therapy for Cancer Treatment with Hybrid Membrane-Camouflaged Mesoporous Silica Gold Nanorods. ACS Appl Mater Interfaces. 2020; 12(52):57732-57745. DOI: 10.1021/acsami.0c18287. View